NCT00186745View on ClinicalTrials.gov

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

NATerminatedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions
Venous ThrombosisPulmonary Embolism
Interventions
DRUG

Tinzaparin

Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.

Trial Locations (1)

L8N 4A6

St Joseph's Healthcare Hamilton, Hamilton

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

Heart and Stroke Foundation of Ontario

OTHER

collaborator

LEO Pharma

INDUSTRY

lead

St. Joseph's Healthcare Hamilton

OTHER